Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alnuctamab + Mezigdomide in Relapsed/Refractory Multiple Myeloma
NCT06163898Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Feb 2024
- Primary completion
- Jun 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of alnuctamab in multiple myeloma (MM) (5 arms), sponsored by Celgene Corporation. Primary endpoints: Adverse Events, Serious Adverse Events and 4 more. Started Feb 2024; status: terminated.
02
Drugs
alnuctamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06163898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06163898.